Julia Dorn

Julia Dorn

Auto-generated profile, based on publicly available information

Julia Dorn

Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in JMIR AI
Verified
Journal Article
Open access
PHPia Hummelsberger
Pia Hummelsberger
TKTimo K Koch
Timo K Koch
SRSabrina Rauh
Sabrina Rauh
JDJulia Dorn
Julia Dorn
ELEva Lermer
Eva Lermer
SGSusanne Gaube
Susanne Gaube
Background: Artificial intelligence (AI) is often promoted as a potential solution for many challenges health care systems face worldwide. However, its implementation in clinical practice lags behind its technological development. Objective: This study aims to gain insights into the current state and prospects of AI technology from the stakeholders most directly involved in its adoption in the health care sector whose perspectives have received limited attention in research to date. Methods: For this purpose, the perspectives of AI researchers and health care IT professionals in North America and Western Europe were collected and compared for profession-specific and regional differences. In this preregistered, mixed methods, cross-sectional study, 23 experts were interviewed using a semistructured guide. Data from the interviews were analyzed using deductive and inductive qualitative methods for the thematic analysis along with topic modeling to identify latent topics. Results: Through our thematic analysis, four major categories emerged: (1) the current state of AI systems in health care, (2) the criteria and requirements for implementing AI systems in health care, (3) the challenges in implementing AI systems in health care, and (4) the prospects of the technology. Experts discussed the capabilities and limitations of current AI systems in health care in addition to their prevalence and regional differences. Several criteria and requirements deemed necessary for the successful implementation of AI systems were identified, including the technology’s performance and security, smooth system integration and human-AI interaction, costs, stakeholder involvement, and employee training. However, regulatory, logistical, and technical issues were identified as the most critical barriers to an effective technology implementation process. In the future, our experts predicted both various threats and many opportunities related to AI technology in the health care sector. Conclusions: Our work provides new insights into the current state, criteria, challenges, and outlook for implementing AI technology in health care from the perspective of AI researchers and IT professionals in North America and Western Europe. For the full potential of AI-enabled technologies to be exploited and for them to contribute to solving current health care challenges, critical implementation criteria must be met, and all groups involved in the process must work together.

3 February 2014 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
PDF file
JDJulia Dorn
Julia Dorn
NBNathalie Beaufort
Nathalie Beaufort
MSManfred Schmitt
Manfred Schmitt
EDEleftherios P Diamandis
Eleftherios P Diamandis
Peter GoettigPeter Goettig
Peter Goettig
VMViktor Magdolen
Viktor Magdolen
Gynecological cancers, including malignant tumors of the ovaries, the endometrium and the cervix, account for approximately 10% of tumor-associated deaths in women of the Western world. For screening, diagnosis, prognosis, and therapy response prediction, the group of enzymes known as serine (Ser-)proteases show great promise as biomarkers. In the present review, following a summary of the clinical facts regarding malignant tumors of the ovaries, the endometrium and the cervix, and characterization of the most important Ser-proteases, we thoroughly review the current state of knowledge relating to the use of proteases as biomarkers of the most frequent gynecological cancers. Within the Ser-protease group, the kallikrein-related peptidase (KLK) family, which encompasses a subgroup of 15 members, holds particular promise, with some acting via a tumor-promoting mechanism and others behaving as protective factors. Further, the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 (plasminogen activator inhibitor-1) seem to play an unfavorable role in gynecological tumors, while down-regulation of high-temperature requirement proteins A 1, 2 and 3 (HtrA1,2,3) is associated with malignant disease and cancer progression. Expression/activity levels of other Ser-proteases, including the type II transmembrane Ser-proteases (TTSPs) matriptase, hepsin (TMPRSS1), and the hepsin-related protease (TMPRSS3), as well as the glycosyl-phosphatidylinositol (GPI)-anchored Ser-proteases prostasin and testisin, may be of clinical relevance in gynecological cancers. In conclusion, proteases are a rich source of biomarkers of gynecological cancer, though the enzymes’ exact roles and functions merit further investigation.

10 December 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
KPKonstantina Panoutsopoulou
Konstantina Panoutsopoulou
PMParaskevi Magkou
Paraskevi Magkou
TDTobias Dreyer
Tobias Dreyer
JDJulia Dorn
Julia Dorn
EOEva Obermayr
Eva Obermayr
ASAndreas Scorilas
Andreas Scorilas

27 April 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
TDTobias Dreyer
Tobias Dreyer
SKSabine Kuhn
Sabine Kuhn
CSChristoph Stange
Christoph Stange
NHNadine Heithorst
Nadine Heithorst
DSDaniela Schilling
Daniela Schilling
HBHolger Bronger
Holger Bronger
A crucial mode of action of trastuzumab is the labeling of HER2-positive (HER2+) tumor cells for the eradication by natural killer (NK) cells, a process called antibody-dependent cellular cytotoxicity (ADCC). However, despite widespread HER2 expression among cancer entities, only a fraction, with robust HER2 overexpression, benefits from trastuzumab therapy. ADCC requires both sufficient lymphocytic infiltration and close binding of the immune cells to the antibody-tagged tumor cells. We hypothesized that the chemokine CX3CL1 could improve both processes, as it is synthesized as a membrane-bound, adhesive form that is eventually cleaved into a soluble, chemotactic protein. Here, we show that CX3CL1 overexpression is a positive prognostic marker in breast cancer. CX3CL1 overexpression attracted tumor-suppressive lymphocytes, including NK cells, and inhibited tumor growth and lung metastasis in the syngeneic 4T1 breast cancer mouse model. In HER2+ SKBR3, MDA-MB-453, and HT-29 tumor cells, CX3CL1 overexpression increased NK cell–mediated cytotoxicity in vitro and acted synergistically with trastuzumab. Even though CX3CL1 did not further improve trastuzumab efficacy in vivo in the trastuzumab-sensitive MDA-MB-453 model, it compensated for NK-cell depletion and prolonged survival. In the HER2 low–expressing HT-29 model, however, CX3CL1 overexpression not only prolonged survival time but also overcame trastuzumab resistance in a partly NK cell–dependent manner. Taken together, these findings identify CX3CL1 as a feasible pharmacologic target to enable trastuzumab therapy in HER2 low–expressing cancers and render it a potential predictive biomarker to determine therapy responders.

14 April 2021 in Research Square
Verified
Preprint
Open access
PDF file
YLYueyang Liu
Yueyang Liu
SPSarah Preis
Sarah Preis
GXGeng Xiaocong
Geng Xiaocong
WGWeiwei Gong
Weiwei Gong
MKMarion Kiechle
Marion Kiechle
JDJulia Dorn
Julia Dorn
Background. Triple-negative breast cancer (TNBC) is a breast cancer subtype with poor prognosis and limited targeted therapy options. Multiple KLKs have been described to play key roles in carcinogenesis and metastasis of breast cancer. Purpose. In the present study, the clinical significance of KLK8, KLK10, and KLK11 mRNA expression in tumor tissue of TNBC patients was investigated. Methods. The mRNA expression levels of KLK8, 10, and 11 were quantified by quantitative PCR and their prognostic values were analyzed in a large, well-characterized TNBC cohort (n = 123). Results. Significantly positive correlations were observed between all three KLK mRNA levels indicating coordinate expression of these proteases in TNBC. In univariate analyses, both elevated KLK8, KLK10 as well as all combinations of the three factors (KLK8 + KLK10, KLK8 + KLK11, KLK10 + KLK11, KLK8 + KLK10 + KLK11) were significantly associated with shortened disease-free survival (DFS), while high mRNA levels of KLK11, as well as KLK10 + KLK11 were significantly associated with shortened overall survival (OS). In multivariate Cox regression analyses, KLK10 and all combined factors remained unfavorable independent predictive markers for DFS, while high KLK11 mRNA expression represented an unfavorable independent predictor for OS. Conclusions. Increased KLK8, KLK10, and KLK11 mRNA expression levels are associated with unfavorable prognosis in triple-negative breast cancer. The combination of KLK8 + KLK10 + KLK11 may represent a stronger prognostic biomarker for DFS than KLK8, KLK10, KLK11 alone, or other combinations thereof, whereas KLK11 mRNA expression is an independent prognostic biomarker for OS in TNBC patients.

4 April 2023
Verified
Other
Open access
TDTobias Dreyer
Tobias Dreyer
SKSabine Kuhn
Sabine Kuhn
CSChristoph Stange
Christoph Stange
NHNadine Heithorst
Nadine Heithorst
DSDaniela Schilling
Daniela Schilling
HBHolger Bronger
Holger Bronger